EFFICACY OF VIMPAT (LACOSAMIDE) TN THE TREATMENT OF DRUG-RESISTANT CRYPTOGENIC FOCAL EPILEPSY WITH FOCAL AUTOMOTOR AND SECONDARILY GENERALIZED SEIZURES (A CLINICAL CASE)
https://doi.org/10.17650/2073-8803-2012-7-2-3-12
Abstract
Despite the considerable advances of epileptology drug-resistant epilepsies consist about 30% among all forms of epilepsy. A case of successful using of a new antiepileptic drug lacosamide (vimpat) in the treatment of 31 years old patient with the resistant form of cryptogenic focal epilepsy with focal automotor and secondarily generalized seizures is presented. Authors represent the review of the literature devoted to efficacy and tolerability of lacosamide in the treatment of drug-resistant epilepsy.
About the Authors
M. B. Mironov
Институт детской неврологии и эпилепсии имени Святителя Луки, Москва
Russian Federation
Russian Federation
K. Yu. Mukhin
Институт детской неврологии и эпилепсии имени Святителя Луки, Москва
Russian Federation
Russian Federation
O. A. Pylaeva
Институт детской неврологии и эпилепсии имени Святителя Луки, Москва
Russian Federation
Russian Federation
References
1. Зенков Л.Р. Противоэпилептический препарат лакосамид (вимпат) // Журн неврол психиатр. — 2010. — Т. 110. — №10. — С. 72–79.
2. Воронкова К.В., Пылаева О.А., Федин А.И. Современные принципы лечения фокальных эпилепсий // Эпилепсия. — 2011. — №1 (4). — С. 2–14.
3. Мильчакова Л.Е., Гехт А.Б. Эффективность и безопасность нового противоэпилептического препарата лакосамид у больных фокальной эпилепсией (данные двойных слепых плацебо-контролируемых исследований) // Журн неврол психиатр. — 2010. — Т. 110, N 3. — вып. 2. — С. 39–43.
4. Мухин К.Ю., Петрухин А.С., Миронов М.Б. Эпилептические синдромы. Диагностика и терапия (справочное руководство) // М.: Системные решения, 2008. — 224 с.
5. Мухин К.Ю., Тысячина М.Д., Глухова Л.Ю., Фрейдкова Н.В. Клинический случай применения лакосамида (вимпат) в лечении резистентной формы симптоматической фокальной эпилепсии // Рус. жур. дет. невр. — 2011. — Т. VI. — Вып. 2. — С. 37–42.
6. Benhaddi H., Gunn A., Ferro B. Medico-economic evaluation of lacosamide adjunctive therapy in the treatment of patients with refractory epilepsy in Scotland and Spain //13 th Annual European Congress: health technology assessment 6-9 November 2010, Prague.
7. Ben-Menachem E., Biton V., Jatuzis D., Abou-Khalil B., Doty P., Rudd G.D. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures // Epilepsia. — 2007. — V. 48(7). — P. 1308–17.
8. Ben-Menachem E. Lacosamide: an investigational drug for adjunctive treatment of partial-onset seizures // Drugs Today (Barc). — 2008. — V. 44(1). — P. 35–40.
9. Biton V., Rosenfeld W.E., Whitesides J., Fountain N.B., Vaiciene N., Rudd G.D. Intravenous lacosamide as replacement for oral lacosamide in patients with partial-onset seizures // Epilepsia. — 2008. — V. 49(3). — P. 418–24.
10. Bolin K., Berggren F., Forsgren L. Lacosamide as treatment of epileptic seizures — cost utility results for Sweden // Acta Neurol Scand. — 2010. — V. 121(6). — P. 406–12.
11. Chung S., Sperling M.R., Biton V., Krauss G., Hebert D., Rudd G.D., Doty P.; SP754 Study Group. Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial // Epilepsia. — 2010. — V. 51(6). — P. 958–67.
12. Chung S., Ben-Menachem E., Sperling M.R., Rosenfeld W., Fountain N.B., Benbadis S., Hebert D., Isojarvi J., Doty P. Examining the clinical utility of lacosamide: pooled analyses of three phase II/III clinical trials // CNS Drugs. — 2010. — V. 24(12). — P. 1041–54.
13. Elger C.E., Schmidt D. Modern management of epilepsy: A practical approach // Epilepsy & Behavior. — 2008. — V. 12. — P. 501–539.
14. Errington A.C., Coyne L., Stohr T., Selve N., Lees G. Seeking a mechanism of action for the novel anticonvulsant lacosamide // Neuropharmacology. — 2006. — V. 50(8). — P. 1016–29.
15. Errington A.C., Stohr T., Heers C., Lees G. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels // Mol Pharmacol. — 2008. — V. 73(1). — P. 157–69.
16. Freitag J.M., Beyreuther B., Heers C., Stoehr T. Lacosamide modulates collapsin response mediator protein 2 (CRMP-2) // Epilepsia. — 2007. — V. 48. — P. 320.
17. Gavatha M., Ioannou I., Papavasiliou A.S. Efficacy and tolerability of oral lacosamide as adjunctive therapy in pediatric patients with pharmacoresistant focal epilepsy // Epilepsy Behav. — 2011. — V. 20(4). — P. 691–3.
18. Garcia-Morales I., Delgado R.T., Falip M., Campos D., Garcia M.E., Gil-Nagel A. Early clinical experience with lacosamide as adjunctive therapy in patients with refractory focal epilepsy and nocturnal seizures // Seizure. — 2011. — V. 20(10). — P. 801–4.
19. Gil-Nagel A., Marin H. Lacosamide: a new generation in the treatment of epilepsy // Rev Neurol. — 2011. —V. 52 (3). — P. 159–62.
20. Glauser T., Ben-Menachem E., Bourgeois B., Cnaan A., Chadwick D., Guerreiro C., et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes // Epilepsia. — 2006. — V. 47. — P. 1094–120.
21. Guilhoto L.M., Loddenkemper T., Gooty V.D., Rotenberg A., Takeoka M., Duffy F.H., Coulter D., Urion D., Bourgeois B.F., Kothare S.V. Experience with lacosamide in a series of children with drug-resistant focal epilepsy // Pediatr Neurol. — 2011. — V. 44(6). — P. 414–9.
22. Halasz P., Kalviainen R., Mazurkiewicz-Beldzinska M., Rosenow F., Doty P., Hebert D., Sullivan T; SP755 Study Group. Adjunctive lacosamide for partial-onset seizures: Efficacy and safety results from a randomized controlled trial // Epilepsia. — 2009. — V. 50(3). — P. 443–53.
23. Hao X.T., Wong I.S., Kwan P. Interrater reliability of the international consensus definition of drug-resistant epilepsy: a pilot study // Epilepsy Behav. — 2011. — V. 22(2). — P. 388–90.
24. Harden C.L., Cohn A., Lowe M., Serrano E. Initial post marketing experience with lacosamide in adult patients with epilepsy // Epilepsy Res. — 2011 Oct 18. [Epub ahead of print]
25. Harris J.A., Murphy J.A. Lacosamide and Epilepsy // CNS Neurosci Ther. — 2010 Oct 15. doi: 10.1111/j.1755-5949.2010.00198.x.
26. Harris J.A., Murphy J.A. Lacosamide: an adjunctive agent for partial-onset seizures and potential therapy for neuropathic pain // Ann Pharmacother. — 2009. — V. 43(11). — P. 1809–17.
27. Johannessen S.I., Ben-Menachem E. Management of Focal-Onset Seizures. An Update on Drug Treatment // Drugs. — 2006. — V. 66 (13). — P. 1701–1725.
28. Kelemen A., Halasz P. Lacosamide for the prevention of partial onset seizures in epileptic adults // Neuropsychiatr Dis Treat. — 2010. — V. 6. — P. 465–71.
29. Kellinghaus C. Lacosamide as treatment for partial epilepsy: mechanisms of action, pharmacology, effects, and safety // Ther Clin Risk Manag. — 2009. — V. 5. — P. 757–66.
30. Krauss G., Ben-Menachem E., Mameniskiene R., Vaiciene-Magistris N., Brock M., Whitesides J.G., Johnson M.E.; SP757 Study Group. Intravenous lacosamide as short-term replacement for oral lacosamide in partial-onset seizures // Epilepsia. — 2010. — V. 51(6). — P. 951–7.
31. Kwan P., Brodie M.J. Refractory epilepsy: mechanisms and solutions // Expert Rev Neurother. — 2006. — V. 6(3). — P. 397–406.
32. Kwan P., Brodie M.J. Epilepsy after the first drug fails: substitution or add-on? // Seizure. — 2000. — V. 9 (7). —P. 464–8.
33. Kwan P., Brodie M.J. Early identification of refractory epilepsy // N Engl J Med. — 2000. — V. 342(5). — P. 314–9.
34. O'Brien T.J., Mosewich R.K., Britton J.W., Cascino G.D., So E.L. History and seizure semiology in distinguishing frontal lobe seizures and temporal lobe seizures // Epilepsy Res. — 2008. — V. 82(2–3). — P. 177–82.
35. Panayotopoulos С.P. Principles of Therapy in the Epilepsies / In: Panayotopoulos. A Clinical Guide to Epileptic Syndromes and their Treatment. — Springer, 2007. — P. 155–184.
36. Rosenow F., Knake S. Recent and future advances in the treatment of status epilepticus // Ther Adv Neurol Disord. — 2008. — V. 1(1). — P. 33–42.
37. Simoens S. Lacosamide as adjunctive therapy for partial-onset epileptic seizures: a review of the clinical and economic literature // Curr Med Res Opin. — 2011 May 12.
38. Simoens S. Budget impact analysis of adjunctive therapy with lacosamide for partial-onset epileptic seizures in Belgium // J Med Econ. — 2011. — V. 14(3). — P. 299–304.
Review
For citations:
Mironov M.B., Mukhin K.Yu., Pylaeva O.A. EFFICACY OF VIMPAT (LACOSAMIDE) TN THE TREATMENT OF DRUG-RESISTANT CRYPTOGENIC FOCAL EPILEPSY WITH FOCAL AUTOMOTOR AND SECONDARILY GENERALIZED SEIZURES (A CLINICAL CASE). Russian Journal of Child Neurology. 2012;7(2):3-12. (In Russ.) https://doi.org/10.17650/2073-8803-2012-7-2-3-12
Views:
1158
Email this article 